temujin
5th March 2008, 07:14 AM
Dear Forum,
I am not sure how to interpret this section taken from the foreword of the document "Guidance for Industry Part 11, Electronic Records; Electronic Signatures - Scope and Application"
This guidance explains that we will narrowly interpret the scope of part 11. While the re-examination of part 11 is under way, we intend to exercise enforcement discretion with respect to certain part 11 requirements. That is, we do not intend to take enforcement action to enforce compliance with the validation, audit trail, record retention, and record copying requirements of part 11 as explained in this guidance. However, records must still be maintained or submitted in accordance with the underlying predicate rules, and the Agency can take regulatory action for noncompliance with such predicate rules.
In addition, we intend to exercise enforcement discretion and do not intend to take (or recommend) action to enforce any part 11 requirements with regard to systems that were operational before August 20, 1997, the effective date of part 11 (commonly known as legacy systems) under the circumstances described in section III.C.3 of this guidance.
Note that part 11 remains in effect and that this exercise of enforcement discretion applies only as identified in this guidance.
Does it mean that FDA will not expect to see e.g. a validation report of a system that holds electronic records?
By the way, does anyone know for how long this "enforcement discretion" will last?
confused.
regards
t.
I am not sure how to interpret this section taken from the foreword of the document "Guidance for Industry Part 11, Electronic Records; Electronic Signatures - Scope and Application"
This guidance explains that we will narrowly interpret the scope of part 11. While the re-examination of part 11 is under way, we intend to exercise enforcement discretion with respect to certain part 11 requirements. That is, we do not intend to take enforcement action to enforce compliance with the validation, audit trail, record retention, and record copying requirements of part 11 as explained in this guidance. However, records must still be maintained or submitted in accordance with the underlying predicate rules, and the Agency can take regulatory action for noncompliance with such predicate rules.
In addition, we intend to exercise enforcement discretion and do not intend to take (or recommend) action to enforce any part 11 requirements with regard to systems that were operational before August 20, 1997, the effective date of part 11 (commonly known as legacy systems) under the circumstances described in section III.C.3 of this guidance.
Note that part 11 remains in effect and that this exercise of enforcement discretion applies only as identified in this guidance.
Does it mean that FDA will not expect to see e.g. a validation report of a system that holds electronic records?
By the way, does anyone know for how long this "enforcement discretion" will last?
confused.
regards
t.





